🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Brian F. Kiesel

University of Pittsburgh

ORCID: 0000-0002-4214-7524

Also affiliated with Bristol-Myers Squibb (United States), UPMC Hillman Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer”.

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer

Cancer Chemotherapy and Pharmacology(2022)10.1007/s00280-022-04430-6
N/A
0.560DataRank · unranked
10 citations

Shannon Puhalla, Shalu Pahuja, Fei Ding, Yan Lin, Leonard J. Appleman +30 more

Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice

Cancer Chemotherapy and Pharmacology(2022)10.1007/s00280-022-04436-0
N/A
0DataRank · unranked
8 citations

Joshua J. Deppas, Jianxia Guo, Robert A. Parise, David A. Clump, Christopher J. Bakkenist +2 more

Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up

Cancer Chemotherapy and Pharmacology(2020)10.1007/s00280-020-04030-2
N/A
0DataRank · unranked
24 citations

Allison L. Brodsky, Joseph A. Sparano, Stephanie V. Blank, Mimi Kim, Dawn L. Hershman +6 more

Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04675-3
N/A
0DataRank · unranked
4 citations

Brian F. Kiesel, Jianxia Guo, Robert A. Parise, David A. Clump, David Z. D’Argenio +3 more

The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04651-x
N/A
0DataRank · unranked
1 citations

Naoko Takebe, Alice P. Chen, Shivaani Kummar, Richard Piekarz, Brian F. Kiesel +5 more

Comparative in vivo toxicology of ATR inhibitors ceralasertib, elimusertib, and berzosertib alone and in combination with ionizing radiation

Toxicology and Applied Pharmacology(2025)10.1016/j.taap.2025.117375
N/A
0DataRank · unranked
4 citations

Brian F. Kiesel, Jianxia Guo, Lora H. Rigatti, Joseph D. Latoche, Anthony R. Green +7 more

A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-06889-0
N/A
0DataRank · unranked
8 citations

Shalu Pahuja, Brian F. Kiesel, Leonard J. Appleman, Fei Ding, Yan Lin +13 more